Professor John Fraser AO Presents at the Food Allergy Fund Innovation & Investment Summit
April 30, 2025
In April 2025, Professor John Fraser AO, Founder and Chief Medical Officer of DMC had the privilege of presenting at the prestigious Food Allergy Fund Summit in New York. John shared the progress being made on DMC’s Epinephrine Inhaler that is currently in development, targeting rapid treatment of Anaphylaxis.
Watch the full presentation here.
About DMC
DMC is a clinical stage medtech company founded in Brisbane, Australia by globally recognised intensive care specialist, researcher, entrepreneur and founder Professor John Fraser AO.
DMC is developing a proprietary inhaled drug delivery platform for use in critical care emergencies. Our lead asset is an investigational inhaled epinephrine product to treat anaphylaxis.
DMC has a strong suite of intellectual property portfolio protecting both its inhaled drug delivery platform and therapeutic formulations. To date, DMC has raised more than AU$30 million from both private and public sector investors.
